Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25:29:30-35.
doi: 10.1016/j.euros.2021.04.009. eCollection 2021 Jul.

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

Jeffrey J Tosoian  1   2   3 , Rodney L Dunn  1 , Yashar S Niknafs  3 , Anjan Saha  3 , Randy A Vince Jr  1   2 , Jennifer L St Sauver  4 , Debra J Jacobson  4 , Michaela E McGree  4 , Javed Siddiqui  1   3 , Jack Groskopf  5 , Steven J Jacobsen  6 , Scott A Tomlins  1   2   3 , Lakshmi P Kunju  1   7 , Todd M Morgan  1   2 , Simpa S Salami  1   2   3 , John T Wei  1 , Arul M Chinnaiyan  1   2   3   7   8 , Aruna V Sarma  1   9
Affiliations

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

Jeffrey J Tosoian et al. Eur Urol Open Sci. .

Abstract

Background: Serum prostate-specific antigen (PSA), used in prostate cancer screening, is nonspecific for cancer and is affected by age and prostate volume. More specific biomarkers could be more accurate for early detection of prostate cancer and reduce unnecessary prostate biopsies.

Objective: To evaluate the association of age and prostate volume with urinary MyProstateScore (MPS) in a screened, longitudinal cohort without evidence of prostate cancer.

Design setting and participants: The Olmsted County Study included men aged 40-79 yr who underwent biennial prostate cancer screening. PSA ≥4.0 ng/ml or abnormal rectal examination triggered prostate biopsy, and patients with cancer were excluded. The remaining men submitted urinary specimens for PCA3 and TMPRSS2:ERG testing.

Outcome measurements and statistical analysis: MPS was calculated using the validated, locked model for grade group ≥2 cancer that includes serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. The associations of age and volume with biomarkers were assessed in multivariable regression models. The t statistic was used to quantify the strength of associations independent of the unit of measurement, and R 2 values were used to estimate the proportion of biomarker variance explained by each factor.

Results and limitations: The study included 314 screened men without evidence of cancer. In multivariable models including age and volume, PCA3 score was significantly associated with age (t = 7.51; p < 0.001), while T2:ERG score was not associated with age or volume. MPS was significantly associated with both age (t = 7.45; p < 0.001) and volume (t = 3.56; p < 0.001), but accounting for age alone explained the variability observed (R 2 = 0.29) in a similar way to the model including age and volume (R 2 = 0.31). The variability of PCA3, T2:ERG, and MPS was less dependent on age and volume than the variability for PSA (R 2 = 0.45).

Conclusions: In a cohort of longitudinally screened men without evidence of cancer, we found that MPS demonstrated less variability with noncancer factors (age, prostate volume) than PSA did. These findings support the biology of these markers as more cancer-specific than PSA and highlight their promise in reducing the morbidity associated with PSA-based screening.

Patient summary: In a group of men with no evidence of prostate cancer, we found that each of three urine-based markers of cancer-PCA3, T2:ERG, and the commercially available MyProstateScore test-showed less variability with noncancer factors (age and prostate volume) than serum PSA (prostate-specific antigen) did. These findings support their proposed use as noninvasive markers of prostate cancer that could improve the accuracy of early detection.

Keywords: Biomarkers; Genomics; Prostate cancer; Prostate cancer screening.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cooperberg M.R., Moul J.W., Carroll P.R. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146–8151. doi: 10.1200/JCO.2005.02.9751. - DOI - PubMed
    1. Thompson I.M., Ankerst D.P., Chi C. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66–70. doi: 10.1001/jama.294.1.66. - DOI - PubMed
    1. Schröder F.H., Carter H.B., Wolters T. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008;53:468–477. doi: 10.1016/j.eururo.2007.10.047. - DOI - PubMed
    1. Mettlin C., Jones G., Averette H., Gusberg S.B., Murphy G.P. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42–46. doi: 10.3322/canjclin.43.1.42. - DOI - PubMed
    1. Benson M.C., Whang I.S., Pantuck A. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815–816. - PubMed